Single centre experience on the use of low dose subcutaneous cytarabine in treatment of patients with high-risk myelodysplastic syndrome and acute myeloid leukaemia

被引：0
|
作者：
Schneider, T. [1 ]
Narayanan, S. [1 ]
机构：
[1] Univ Hosp Southampton NHS Fdn Trust, Dept Haematol, Southampton, Hants, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
161
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [21] Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia
    Anargyrou, K
    Vaiopoulos, G
    Terpos, E
    Tsironi, M
    Konstantopoulos, K
    Samarkos, M
    Meletis, J
    HAEMATOLOGIA, 2002, 32 (02) : 169 - 173
  • [22] Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia
    Denzlinger, C
    Bowen, D
    Benz, D
    Gelly, K
    Brugger, W
    Kanz, L
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (01) : 93 - 95
  • [23] Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome
    Roboz, Gail J.
    Ritchie, Ellen K.
    Curcio, Tania
    Samuel, Michael
    Provenzano, Juliette
    Segovia, Javier
    Christos, Paul J.
    Mathew, Susan
    Allen-Bard, Sandra
    Feldman, Eric J.
    LEUKEMIA RESEARCH, 2011, 35 (04) : 522 - 525
  • [24] Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
    Kadia, Tapan M.
    Reville, Patrick K.
    Borthakur, Gautam
    Yilmaz, Musa
    Kornblau, Steven
    Alvarado, Yesid
    Dinardo, Courtney D.
    Daver, Naval
    Jain, Nitin
    Pemmaraju, Naveen
    Short, Nicholas
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Islam, Rabiul
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop M.
    LANCET HAEMATOLOGY, 2021, 8 (08): : E552 - E561
  • [25] A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60years of age
    Buckley, Sarah A.
    Mawad, Raya
    Gooley, Ted A.
    Becker, Pamela S.
    Sandhu, Vicky
    Hendrie, Paul
    Scott, Bart L.
    Wood, Brent L.
    Walter, Roland B.
    Smith, Kelly
    Dean, Carol
    Estey, Elihu H.
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 349 - 355
  • [26] Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia
    Oosterveld, M
    de Witte, T
    BLOOD REVIEWS, 2000, 14 (04) : 182 - 189
  • [27] Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Chen, Tara L.
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Rol B.
    Becker, Pamela S.
    Pagel, John M.
    Estey, Elihu H.
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 483 - 486
  • [28] Outcomes of the patients with myelodysplastic syndrome, acute myeloid leukaemia with multilineage dysplasia and treatment-related acute myeloid leukaemia after allogeneic stem cell transplantation. A single-centre experience
    Steinerova, K.
    Koza, V.
    Jindra, P.
    Lysak, D.
    Karas, M.
    Svoboda, T.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S189 - S189
  • [29] Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Shadman, Mazyar
    Mawad, Raya
    Dean, Carol
    Shannon-Dorcy, Kathleen
    Sandhu, Vicky
    Hendrie, Paul C.
    Scott, Bart L.
    Walter, Roland B.
    Becker, Pamela S.
    Pagel, John
    Estey, Elihu H.
    BLOOD, 2014, 124 (21)
  • [30] Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome
    Yanada, Masamitsu
    Huang, Xuelin
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Faderl, Stefan
    Issa, Jean-Pierre
    Kantarjian, Hagop
    Estey, Elihu
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 555 - 557
12345